

# Tomotake Shirono

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3670584/publications.pdf>

Version: 2024-02-01

24  
papers

525  
citations

759233

12  
h-index

677142

22  
g-index

25  
all docs

25  
docs citations

25  
times ranked

705  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. <i>Cancers</i> , 2020, 12, 1867.	3.7	56
2	Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. <i>Cancer Medicine</i> , 2015, 4, 1836-1843.	2.8	54
3	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. <i>Cancers</i> , 2021, 13, 2786.	3.7	44
4	Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. <i>Oncology Letters</i> , 2020, 20, 2257-2265.	1.8	44
5	Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision tree analysis after propensity score matching. <i>Hepatology Research</i> , 2019, 49, 919-928.	3.4	42
6	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. <i>Cancers</i> , 2020, 12, 1010.	3.7	42
7	Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 580-588.	2.8	41
8	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. <i>Cancers</i> , 2021, 13, 160.	3.7	38
9	Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1013-1020.	1.0	27
10	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. <i>Nutrients</i> , 2020, 12, 1076.	4.1	27
11	Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. <i>Hepatology Communications</i> , 2020, 4, 1218-1228.	4.3	21
12	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 646.	3.7	19
13	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Cancers</i> , 2021, 13, 5282.	3.7	11
14	Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. <i>Cancers</i> , 2021, 13, 4450.	3.7	10
15	Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 96, 79-86.	1.9	9
16	Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 558-565.	1.9	9
17	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 987.	2.4	7
18	Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 19, 2667-2676.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. <i>Oncology</i> , 2019, 96, 192-199.	1.9	4
20	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. <i>Oncology</i> , 2021, 99, 756-765.	1.9	4
21	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. <i>Cancers</i> , 2022, 14, 2295.	3.7	3
22	Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Hepatology Communications</i> , 2022, 6, 2594-2604.	4.3	3
23	Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 8.	1.0	2
24	Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors. <i>Japanese Journal of Radiology</i> , 2021, , 1.	2.4	1